Merck Updates Plans for Headquarters Move in New Jersey
Company to Close Summit Campus; Move Global HQ to Kenilworth
WHITEHOUSE STATION, N.J. -- October 1, 2013
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today
announced plans to move its global headquarters from Whitehouse Station, N.J.,
to its existing facilities in Kenilworth, N.J. The company had previously
announced that it would close its Whitehouse Station building and relocate its
global headquarters to Summit, N.J. However, after re-evaluating its real
estate needs in the state, Merck determined that it could achieve greater cost
savings and operational synergies by closing both its Summit campus and its
main Whitehouse Station facility. The transition is expected to begin next
year and be completed by 2015.
These updated plans are part of the company’s global initiative announced
today, to sharpen its commercial and R&D focus and reduce costs, including the
size of its workforce and global real estate footprint.
Merck’s Animal Health and Consumer Care divisions currently located in Summit
will be relocated to another facility in New Jersey. In addition, certain
manufacturing, laboratory and other functions currently located in Summit will
be relocated to other facilities in New Jersey or Pennsylvania.
Merck has been headquartered in Whitehouse Station since 1992. Prior to 1992,
the company was headquartered in Rahway, N.J.
Today's Merck is a global healthcare leader working to help the world be well.
Merck is known as MSD outside the United States and Canada. Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit www.merck.com and
connect with us on Twitter, Facebook and YouTube.
This news release includes “forward-looking statements” within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially from those set
forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest rate
and currency exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approval; Merck’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of Merck’s
patents and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those
described in the forward-looking statements can be found in Merck’s 2012
Annual Report on Form 10-K and the company’s other filings with the Securities
and Exchange Commission (SEC) available at the SEC’s Internet site
Lainie Keller, 908-423-4187
Kelley Dougherty, 908-423-4291
Carol Ferguson, 908-423-4465
Joe Romanelli, 908-423-5185
Press spacebar to pause and continue. Press esc to stop.